Compartmental modelling of the uptake kinetics of the anti-cancer agent topotecan in human breast cancer cells

International Journal of Adaptive Control and Signal Processing

Volumn 19, Issue 5, 2005, Pages 395-417

  Evans, Neil D ^a   Errington, Rachel J ^b   Chapman, Michael J ^c   Smith, Paul J ^b   Chappell, Michael J ^a   Godfrey, Keith R ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Institute for Clean Growth and Future Mobility   (United Kingdom)

Author keywords

Compartmental models; Drug kinetics; Heterogeneity; Identifiability; Topotecan

Indexed keywords

CELLS; DATA ACQUISITION; DNA; MATHEMATICAL MODELS; PARAMETER ESTIMATION; PHARMACOKINETICS; TUMORS;

COMPUTATIONAL MODELS; DURG KINETICS; HETEROGENITY; IDENTIFIABILITY; TOPOTECAN;

BIOLOGICAL ORGANS;

EID: 19944401558     PISSN: 08906327     EISSN: None     Source Type: Journal    
DOI: 10.1002/acs.856     Document Type: Article

References (25)

1. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Current Medicinal Chemistry 2000; 7:39-58.
2. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. European Journal of Cancer 1998; 34(10):1500-1508.
3. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clinical Cancer Research 2002; 8(3):641-661.
4. Hsiang YH, Lui LF. Identification of mammalian DNA topoisomerase-I as an intracellular target of the anticancer drug camptothecin. Cancer Research 1988; 48(7): 1722-1726.
5. Wang JC. DNA topoisomerases. Annual Review of Biochemistry 1996; 65:635-692.
6. Kohn KW, Shao RG, Pommier Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochemistry and Biophysics 2000; 33(2):175-180.
7. Yao S, Murali D, Seetharamulu P, Haridas K, Petluru PNV, Reddy DG, Hausheer FH. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Research 1998; 58(17):3782-3786.
8. Gryczynski I, Gryczynski Z, Lakowicz JR, Yang DZ, Burke TG. Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation. Photochemistry and Photobiology 1999; 69(4):421-428.
9. Evans ND, Errington RJ, Shelley M, Feeney GP, Chapman MJ, Godfrey KR, Smith PJ, Chappell MJ. A mathematical model for the in vitro kinetics of the anti-cancer drug topotecan. Mathematical Biosciences 2004; 189:185-217.
10. Rosing H, Van Zomeren DM, Doyle E, Huinink WWT, Schellens JHM, Suit A, Beijnen JH. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid Chromatographie methods. Journal of Chromatography B 1999; 727(1-2): 191-203.
11. Jacquez JA. Compartmental Analysis in Biology and Medicine (3rd edn). BioMedware: Ann Arbor, 1996.
12. Bellman R, Åström KJ. On structural identifiability. Mathematical Biosciences 1970; 7:329-339.
13. Walter E. Identifiability of State Space Models. Springer: Berlin, 1982.
14. Godfrey KR, DiStefano III JJ. Identifiability of model parameters. In Identifiability of Parametric Models, Chapter 1, Walter E (ed.). Pergamon Press: Oxford, 1987; 1-20.
15. Evans ND, Errington RJ, Shelley M, Feeney GP, Chapman MJ, Godfrey KR, Smith PJ, Chappell MJ. Compartmental modelling to assess stability of topotecan bound to DNA. In Proceedings of the Fifth IFAC Symposium on Modelling and Control in Biomedical Systems, Feng DD, Carson ER (eds), Melbourne, Australia. Pergamon Press: Oxford, 21-23 August, 2003; 403-408.
16. Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfait M. Kinetics of laetone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochimica et Biophysica Acta 1998; 1379(3):353-366.
17. Streltsov SA. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomserase I. Journal of 'Biomolecular Structure and Dynamics 2002; 20;447-454.
18. Pohjanpalo H. System identifiability based on the power series expansion of the solution. Mathematical Biosciences 1978; 41:21-33.
19. Tunali ET, Tarn TJ, New results for identifiability of nonlinear systems. IEEE Transactions on Automatic Control 1987; 32:146-154.
20. Vajda S, Godfrey KR, Rabitz H. Similarity transformation approach to identifiability analysis of nonlinear Compartmental models. Mathematical Biosciences 1989; 93:217-248.
21. Evans ND, Chapman MJ, Chappell MJ, Godfrey KR. Identifiability of uncontrolled nonlinear rational systems. Automatica 2002; 38:1799-1805.
22. Wolfram S. The Mathematíca Book (4th edn). Mathematics Version 4. Wolfram Media/Cambridge University Press: Cambridge, U.K., 1999.
23. Heal KM, Hansen ML, Rickard KM. Maple V Learning Guide (Release 5). Springer: Berlin, New York, 1998.
24. AEA Technology. Facsimile (Version 4.0) Technical Reference. Harwell Laboratory: Didcot, Oxfordshire, U.K., 1995.
25. Clarke GM, Cooke D. A Basic Course in Statistics (4th edn). Arnold: London, 1998.